Updated Data With Larotrectinib in TRK Fusion-Positive Solid Tumors
David S. Hong, MD, discusses updated data with larotrectinib (Vitrakvi) in <em>TRK</em> fusion-positive solid tumors at the ESMO Congress 2019.
David S. Hong, MD, deputy director of the Department of investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses updated data with larotrectinib (Vitrakvi) in TRKfusion-positive solid tumors at the ESMO Congress 2019.
The tumor-agnostic TRK inhibitor larotrectinib showed sustained antitumor activity in adult and pediatric patients withTRKfusionpositive cancers, based on updated findings from an integrated analysis of an adult phase I trial, the phase I/II SCOUT pediatric trial, and the phase II adult/adolescent NAVIGATE basket trial.
Lenalidomide Break Possible? Study Shows Hope for MRD-Negative Myeloma
October 7th 2024A new study suggests that patients with multiple myeloma who achieve sustained MRD-negativity for at least three years may be able to discontinue maintenance therapy without compromising their long-term outcomes.
Read More
